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Evolutionary conservation and selection of human disease gene orthologs in the rat and mouse genomes <p>Model organisms have contributed substantially to our understanding of the etiology of human disease as well as having assisted with  the development of new treatment modalities. The availability of the human, mouse and, most recently, the rat genome sequences now per- mit the comprehensive investigation of the rodent orthologs of genes associated with human disease. Here, we investigate whether human  disease genes differ significantly from their rodent orthologs with respect to their overall levels of conservation and their rates of evolution- ary change</p>
Abstract
Background: Model organisms have contributed substantially to our understanding of the etiology of human disease as well as
having assisted with the development of new treatment modalities. The availability of the human, mouse and, most recently, the
rat genome sequences now permit the comprehensive investigation of the rodent orthologs of genes associated with human
disease. Here, we investigate whether human disease genes differ significantly from their rodent orthologs with respect to their
overall levels of conservation and their rates of evolutionary change.
Results: Human disease genes are unevenly distributed among human chromosomes and are highly represented (99.5%) among
human-rodent ortholog sets. Differences are revealed in evolutionary conservation and selection between different categories
of human disease genes. Although selection appears not to have greatly discriminated between disease and non-disease genes,
synonymous substitution rates are significantly higher for disease genes. In neurological and malformation syndrome disease
systems, associated genes have evolved slowly whereas genes of the immune, hematological and pulmonary disease systems have
changed more rapidly. Amino-acid substitutions associated with human inherited disease occur at sites that are more highly
conserved than the average; nevertheless, 15 substituting amino acids associated with human disease were identified as wild-
type amino acids in the rat. Rodent orthologs of human trinucleotide repeat-expansion disease genes were found to contain
substantially fewer of such repeats. Six human genes that share the same characteristics as triplet repeat-expansion disease-
associated genes were identified; although four of these genes are expressed in the brain, none is currently known to be
associated with disease.
Conclusions: Most human disease genes have been retained in rodent genomes. Synonymous nucleotide substitutions occur
at a higher rate in disease genes, a finding that may reflect increased mutation rates in the chromosomal regions in which disease
genes are found. Rodent orthologs associated with neurological function exhibit the greatest evolutionary conservation; this
suggests that rodent models of human neurological disease are likely to most faithfully represent human disease processes.
However, with regard to neurological triplet repeat expansion-associated human disease genes, the contraction, relative to
human, of rodent trinucleotide repeats suggests that rodent loci may not achieve a 'critical repeat threshold' necessary to
undergo spontaneous pathological repeat expansions. The identification of six genes in this study that have multiple
characteristics associated with repeat expansion-disease genes raises the possibility that not all human loci capable of facilitating
neurological disease by repeat expansion have as yet been identified.
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Background
Human gene mutations resulting in specific disease pheno-
types were first reported in the scientific literature over 50
years ago [1,2]. Since then, protein and nucleotide sequence
changes associated with human disease have accumulated at
a rapid rate. A large body of literature has appeared on human
disease-associated mutations, normal sequence variation,
and alterations that acquire pathological significance when
combined with other deleterious alleles or second-site muta-
tions. With this information compiled into organized data-
bases [3,4], it is now possible to conduct large-scale,
comprehensive analyses of human disease genes. Such stud-
ies acquire additional discriminatory power with the availa-
bility of multiple genome sequences from model organisms,
as comparative studies can provide novel evolutionary
insights into the selective relevance of genetic changes. In the
present study, we have used a collection of nearly 1,200
human disease gene sequences to perform a large-scale anal-
ysis of gene and sequence conservation.
Investigation of evolutionary rates among large sets of genes
has become feasible with the availability of the genome
sequences of human, mouse and rat [5-8]. The degree of
selective pressure to which genes have been subjected is
reflected by the ratio of KA, the number of non-synonymous
substitutions per non-synonymous site, to KS, the number of
synonymous substitutions per synonymous site [9]. Hurst
and Smith [10] have compared these ratios for 'essential'
mammalian genes (that is, those that are lethal or infertile in
genetic knock-out experiments) to those for genes that pro-
duce a viable and fertile phenotype when subject to genetic
knock-out (non-essential genes). Using a sample size of 67
essential genes and 108 non-essential genes, these authors
showed that essential genes manifested significantly lower
KA/KS ratios than non-essential genes. Upon further analysis
however, they found that immune-system genes, which have
high KA/KS values, accounted for much of this effect since
these loci were over-represented in the non-essential gene
set. Analyses of evolutionary rates must therefore account for
rate variation across different tissues.
Using a larger dataset (2,400 human-rodent orthologs and
834 rat-mouse orthologs) and EST information, Duret and
Mouchiroud [11] observed that tissue-specific genes, on aver-
age, exhibited higher KA/KS ratios than genes expressed in
most tissues (so-called 'housekeeping genes'). A more recent
study of microarray data confirmed this finding, and demon-
strated that much of this effect is explicable in terms of a cor-
relation between a gene's tissue-specificity and the cellular
localization of its encoded protein [12].
In this study, we have used genes predicted from the com-
pleted mouse, rat and human genomes, and a manually vali-
dated set of human disease genes. Our aims were three-fold.
Firstly, we sought to determine whether human disease genes
are collectively distinguishable, with respect to evolutionary
conservation and evolutionary rates, from non-disease genes.
Then we investigated whether genes ascribed to different
pathophysiological systems exhibit significant differences in
evolutionary rates. The results promise to be relevant for the
consideration of different types of animal models utilized to
investigate the mechanisms of human disease. Finally, we
considered the category of human disease genes harboring
expansions of trinucleotide repeats. For these genes, a mod-
erate number of repeats is usually compatible with a normal
phenotype, whereas further expansions are frequently associ-
ated with a neurological disease phenotype. We studied poly-
glutamine repeats in rat, mouse and human orthologous
sequences to obtain an evolutionary perspective on the mech-
anisms of glutamine-repeat generation.
Results and discussion
Conservation of human disease genes in the rat 
genome
We considered 1,180 nuclear genes listed in the Human Gene
Mutation Database for which missense or nonsense muta-
tions have been reported to be associated with inherited dis-
ease [3]. Of these entries, 1,124 were successfully mapped to
1,112 Ensembl human genes (see Materials and methods).
Analysis of the distribution of disease genes to human chro-
mosomes (Table 1) indicated that chromosomes 21 and X
were particularly enriched in disease genes. The basis for the
enrichment of these genes on chromosome 21 is unclear, but
the enrichment on the X chromosome is probably due to the
obligatory expression of recessive phenotypes in males where
recessive mutations are necessarily hemizygous. This unique
feature of sex-linked inheritance results in the greater
phenotypic expression of recessive alleles in carrier popula-
tions thereby facilitating both clinical phenotype identifica-
tion, and genetic and mutational analysis.
Of these 1,112 Ensembl genes, 844 (76%) were found to have
orthologous genes in the rat genome (November 2002 assem-
bly), according to Ensembl [13]. This is a significantly greater
proportion of Ensembl 1:1 orthologs than is found for the set
of all Ensembl genes (46%). One reason for this difference
might be a higher fidelity of predicting human disease genes
and their rodent orthologs from their genome sequences,
compared with other genes. This would be a consequence of
the greater availability of transcript evidence, principally
cDNA sequences, for disease genes. Imperfections in gene
prediction and genome sequence assembly are the major hin-
drances to accurate orthology prediction.
We next wished to determine whether any of the 268 remain-
ing human disease genes lacked a rat ortholog, perhaps as a
consequence of either pseudogene creation or gene deletion
in the rat lineage. Bearing in mind that certain regions of the
rat genome sequence remain incomplete, that gene and
orthology predictions are inexact, and that additional sources
of sequence information are available, each of the remaininghttp://genomebiology.com/2004/5/7/R47 Genome Biology 2004,     Volume 5, Issue 7, Article R47       Huang et al. R47.3
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Genome Biology 2004, 5:R47
268 human genes were aligned against the rat genome
(assembly versions 2.0 and 3.1), EST, cDNA and protein
sequences using BLAT [14] and BLAST [15]. Using the meth-
ods employed, we were able to assign orthology even if gene-
duplication events had occurred within the human or rat lin-
eages. Detailed inspection of alignments indicated that only
six human disease genes appear to have no orthologous coun-
terparts among available rat sequences.
Of the six missing orthologs, three with known function were
found to be present in mouse sequences: orthologs of human
genes  HLXB9  (homeobox gene HB9), SGSH  (N-sulfoglu-
cosamine sulfohydrolase) and GP6 (glycoprotein VI, platelet)
with LocusLink identifiers 3110, 6448 and 51206, respec-
tively. Hence, these genes might yet be found in the portion of
the rat genome that still remains to be sequenced. Two of the
three genes missing from both mouse and rat appear to have
become pseudogenes relatively recently given that there are
known hamster orthologs [16,17]. These include cholesteryl
ester transfer protein (CETP), which is associated with the
deficiency in CETP activity described in rat and mouse [16]
and Fuc-TIII (FUT3), an α-(1-3)-fucosyltransferase involved
in the synthesis of milk oligosaccharides [18]. A third gene,
KAL1 (encoding the Kallman syndrome, or anosmin-1, pro-
tein) is entirely absent from the sequenced portions of the rat
and mouse genomes. However, rodent Kal-1 genes may yet be
found in the pseudoautosomal regions of their genomes [19].
Kal-1 is present in Caenorhabditis elegans [20], amphibians,
fish and birds, and its rat and mouse orthologs have been
reported to be detectable using an antibody to the human
KAL1 gene product [19].
Thus, of the 1,112 human disease genes examined, evidence
that all are represented as functional genes in the rat genome
was found, except for the six genes discussed above. Clearly,
the set of genes identified as being associated with inherited
disease in humans is highly conserved in the rat genome.
Mapping human disease mutations to rat genes
We compared sequence variants that result in human inher-
ited disease with amino-acid substitutions that have accumu-
lated since the common ancestor of rat and human. In all,
12,549 missense mutations were mapped to codons in the
pairwise alignments of Ensembl human and rat 1:1 orthologs.
As expected, the majority (89.6%) of these sites contain the
same amino acid in both human and rat wild-type sequences.
This exceeds the 82.2% of all sites that are identical for all 1:1
ortholog pairs [8], indicating that such sites are subject to a
greater degree of purifying selection. Of the remaining 10.4%
of sites, 4.6% were unable to be aligned with precision, while
4.9% exhibited amino-acid substitutions in the rat ortholog
that differed from the human disease missense mutations.
The remaining 104 sites each contained an amino acid that is
present for both the human disease-associated variant and
the rat wild-type sequence (see Additional data file 1). We
considered whether these instances might represent genetic
variations in human for which associations with disease were
erroneously noted, were more tenuous or were unvalidated.
Detailed examination of the literature revealed that there was
compelling experimental evidence for a direct causal relation-
ship between the reported sequence variant and human dis-
ease for only 15 of these sites (Table 2). Of these 15, the rodent
sequence is not likely to be in doubt in eight cases because the
mouse sequence is identical to the rat at this site. If the estab-
lishment of the genotype-phenotype relationship is valid in
these cases, then the rat may not represent an appropriate
model for studying the human disease processes associated
with these variants. On the other hand, the results may repre-
sent opportunities to define alternative pathways or differ-
ences in protein structure that could be utilized in therapeutic
intervention. As noted by Gao and Zhang [21], the most likely
explanation for fixation of human disease-associated muta-
tions in the mouse is the presence of other compensatory
changes suggesting that potentially interesting structural or
functional insights may be revealed by these cases.
Table 1
Chromosome distribution of HGMD disease gene set
Chromosome Ensembl gene 
number
Disease genes Disease gene 
percentage
1 2449 115 4.70
2 1706 81 4.75
3 1329 57 4.29
4 1031 39 3.78
5 1138 56 4.92
6 1296 44 3.40
7 1269 51 4.02
8 860 36 4.19
9 1031 45 4.37
10 986 43 4.36
11 1568 77 4.91
12 1207 52 4.31
13 455 25 5.50
14 736 26 3.53
15 797 29 3.64
16 1084 50 4.61
17 1348 68 5.05
18 365 15 4.11
19 1557 55 3.53
20 704 25 3.55
21 192 15 7.81
22 469 25 5.33
X 869 83 9.55R47.4 Genome Biology 2004,     Volume 5, Issue 7, Article R47       Huang et al. http://genomebiology.com/2004/5/7/R47
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Nucleotide substitution rates
We sought to investigate whether synonymous and non-syn-
onymous nucleotide substitution rates differ between disease
genes and other genes. We calculated the KA/KS ratio for each
human and rat 1:1 ortholog pair. By dividing ortholog pairs
into a set that contained known human disease genes, and a
set that contained genes not known to be associated with dis-
ease, we were able to compare their KA/KS distributions. Only
a marginally significant difference was found between these
two distributions using a Kolmogorov-Smirnov test (P  =
0.035) (Figure 1a). This implies that selective pressures have
been applied relatively uniformly between these two gene
classes. However, a highly significant difference (P = 9.4 × 10-
8) was observed between the KS distribution of ortholog pairs
containing human disease genes, and the KS distribution of
pairs not containing disease genes (Figure 1b). A smaller dif-
ference (P = 3.9 × 10-4) was found between the KA distribu-
tions (Figure 1c).
We considered whether the highly significant difference
between the two KS distributions arose from a small number
of outlier disease genes associated with high KS values. How-
ever this appears not to be the case since removal of the top
10% of data points in both datasets did not reduce the diver-
gence of the two distributions (data not shown).
Recently, Smith and Eyre-Walker [22] calculated evolution-
ary rates for rat-human orthologs of 387 human disease genes
and 2,024 non-disease genes, taken from the Duret and
Mouchiroud [11] and Jimenez-Sanchez et al. [23] datasets,
respectively. They noted that KA/KS and KS values were signif-
icantly elevated for disease genes compared with non-disease
genes. Although the findings relating to KS are fully supported
by our study, our results indicate only a modest difference
between KA/KS  distributions of disease, and non-disease,
genes (human-mouse: P = 0.044; human-rat: P = 0.032),
rather than the 24% difference (P  < 0.0001) reported by
Smith and Eyre-Walker [22]. We attribute this difference to
the variation that can arise from sampling error when smaller
gene sets are employed.
One interpretation of the findings reported here is that sub-
stitutions at non-synonymous sites have indirectly affected
silent substitution rates [11,24]. However, such an effect is
unlikely to be highly pronounced since the significance of the
KS distributions' difference was several orders of magnitude
higher than that of the KA/KS distributions. The finding rather
suggests that human disease gene sequences, and their rat
orthologs, have mutated faster than their non-disease coun-
terparts. If so, then it would appear that disease genes differ
from other genes in one respect: they are more frequently
encoded in hypermutable genomic regions. One possibility
that could account for an elevated mutation rate is if the dis-
ease gene set were to contain a disproportionately lower
number of genes expressed in germ cells. This is because
mutations in such genes might be expected to be more fre-
Table 2
Instances where a substituting amino acid in a human disease mutation is identical to the wild-type sequence of the rat genome
Ensembl reference LocusLink 
identifier
Codon start Nucleotide change Amino acid change Disease
ENSP00000318731 355 225 ACA-AAA Thr-Lys Autoimmune lymphoproliferative syndrome
ENSP00000260947 580 295 AAT-AGT Asn-Ser Breast cancer
ENSP00000256993 4607 59 cACA-GCA Thr-Ala*§ Cardiomyopathy, hypertrophic
ENSP00000253496 2161 398 CGG-CAG Arg-Gln Factor XII deficiency
ENSP00000326824 114548 198 cGTG-ATG Val-Met* Familial cold autoinflammatory syndrome
ENSP00000324427 4653 445 GCA-GTA Ala-Val Glaucoma 1, open angle
ENSP00000322421 3039 68 AACg-AAA Asn-Lys Hemoglobin variant
ENSP00000298599 5979 251 cGAG-AAG Glu-Lys*§ Hirschsprung disease
ENSP00000298599 5979 654 tGCC-ACC Ala-Thr Hirschsprung disease
ENSP00000291550 875 354 gGTG-ATG Val-Met* Homocystinuria
ENSP00000250087 23746 302 CGC-CTC Arg-Leu* Leber congenital amaurosis IV
ENSP00000273783 8893 113 CGC-CAC Arg-His* Leukoencephalopathy with vanishing white 
matter
ENSP00000294717 24 1898 CGC-CAC Arg-His* Macular degeneration, age related
ENSP00000310389 6622 53 gGCA-ACA Ala-Thr*§ Parkinson disease
ENSP00000233139 6716 227 CGA-CAA Arg-Gln Steroid-5 alpha-reductase deficiency
*Cases where the mutation is also identical to the wild-type mouse sequence. §These three cases were previously reported as being present in wild-
type mouse sequences [7]).http://genomebiology.com/2004/5/7/R47 Genome Biology 2004,     Volume 5, Issue 7, Article R47       Huang et al. R47.5
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quently repaired by transcription-coupled repair [25,26].
Another possibility is that disease genes are more prevalent in
genomic regions that suffer elevated mutation rates for other,
as yet unknown, reasons. Certainly, neutral rates have been
found to vary significantly between distinct genomic regions
[27].
Human disease genes and pathophysiology-based 
disease systems
A sufficient number of human disease genes have now been
characterized in adequate detail to permit grouping them by
disease system categories for large-scale analysis. We there-
fore categorized 1,178 human disease genes according to
which organ or pathophysiological system the disease best fit-
ted with respect to a specific pathological variant (Additional
data file 2). For example, adenosine-deaminase deficiency is
caused by ADA  gene mutations that reduce or eliminate
enzyme function; these alterations result in frequently fatal
severe combined immunodeficiency owing to the toxicity of
the accumulating substrates, adenosine and 2'-deoxyadenos-
ine. Considering both the nature of the mutation and the gene
it alters, as well as the impact of the resulting disease, this
gene is categorized under both metabolic- and immune-dis-
ease systems. Among the disease-geneset, 889 genes were
categorized into a single disease system whereas 289 genes
were categorized into two systems.
Figure 2 delineates the 16 disease categories employed and
depicts the number of disease genes in each category. 'Neuro-
logical' and 'metabolic' categories together comprised almost
50% of the characterized human disease genes. For some dis-
ease systems, few genes directly causing disease have been
defined. For example, only 17 genes are currently known to
cause pulmonary disease when mutated. Small numbers of
genes identified for a given disease system could be a reflec-
tion of the complexity of the genetic contribution to disease in
that system, particularly for those disease systems requiring
large-scale studies to identify genetic factors (for example,
[28] for asthma, a pulmonary disease). Thus, it may be that
disease systems with few characterized genes may have a
greater number of contributory (or modulating) genes associ-
ated with complex inheritance patterns, relative to other dis-
ease system categories.
Figure 1
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KA/KS, KS, and KA distributions of ortholog pairs for disease versus non- disease genes Figure 1
KA/KS, KS, and KA distributions of ortholog pairs for disease versus non-
disease genes. (a) The KA/KS ratio, (b) KS, the number of synonymous 
substitutions per synonymous site, and (c) KA, the number of non-
synonymous substitutions per non-synonymous sites, were calculated for 
1:1 human:rat orthologs for a set containing human genes associated with 
disease and a set containing human genes not known to be associated with 
disease.R47.6 Genome Biology 2004,     Volume 5, Issue 7, Article R47       Huang et al. http://genomebiology.com/2004/5/7/R47
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Selection mechanisms acting on human disease genes 
in the rat and mouse
Next we investigated whether selection has acted differen-
tially on human disease genes of the 16 disease-system cate-
gories. We determined the human-rat and human-mouse
distributions of KA/KS ratios for these categories; median KA/
KS values are presented in Figure 3. We present median,
rather than mean, KA/KS values as these values are not nor-
mally distributed. For the sam e  r e a s o n  w e  e m p l o y e d  t h e
multi-level, non-parametric Wilcoxon-Kruskal-Wallis analy-
sis to identify the significance of differences between catego-
ries. We then performed two-level comparisons between each
category and the remaining samples. The results of these
analyses are shown in Figure 4. To distinguish between dis-
ease systems with similar results, two closely scoring systems
were tested against each other. For example, when neurolog-
ical-system genes were compared directly with malforma-
tion-syndrome system genes, no significant difference was
observed. However, immune-system genes exhibited signifi-
cantly higher KA/KS values than hematological-system genes
(data not shown). Based on these results, we conclude that, on
average, immune system disease genes exhibit the highest
KA/KS ratios between rat and human, whereas neurological
and malformation-syndrome system genes have the
lowestKA/KS  ratios. Similar results were found for the
analysis based on human-mouse orthologs (gray bars in Fig-
ures 3 and 4).
We find that significant differences exist between the KA/KS
ratio distributions for the different pathophysiological
classes. For example, within the neurological-disease system,
95% of the genes were subject to purifying selection (KA/KS <
0.25). This is in contrast to immune-system disease genes
where only 65% were found to exhibit such low rates. Thus
among all pathophysiological categories, it would appear that
the genes of the neurological-disease system have been con-
strained by purifying selection the most, whilst those of the
immune system have been constrained the least. No genes in
our study met the strict criterion for positive selection (gene-
averaged KA/KS ratios > 1.0), although adaptive evolution is
more likely to have occurred at single sites for genes with
ratios closer to 1.
In contrast to the findings for KA, KS and KA/KS comparing
complete disease and non-disease gene sets, no significant
differences in KS were found among different disease systems
despite known differences among tissues [12]. The significant
differences identified in KA/KS ratios are likely to reflect dif-
ferences in non-synonymous substitution rates (KA) across
different disease systems.
Human disease gene distribution across pathophysiology systems Figure 2
Human disease gene distribution across pathophysiology systems. The horizontal axis represents different disease systems. The vertical axis represents the 
number of genes present in each disease systems; these numbers are provided at the top of each bar. IDE, insufficient disease evidence.
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We next investigated whether these variations in KA/KS ratios
either arose from associations between physiology and
organs or tissues, or were due to intrinsic properties of the
human disease gene set under study. We studied two sets of
genes: 586 sequences that were retrieved from the Human
Proteome Survey Database (HPSD) [29] using gene ontology
(GO) terms associated with immune function; and 761 genes
retrieved using GO terms with neurological associations. Rat,
mouse and human 1:1:1 orthology relationships were availa-
ble for 200 of these 586 'immune' category genes (Additional
data file 3) and for 304 genes of the 761 'neurological' genes
(Additional data file 4); orthologs of human disease genes
were disallowed from these sets.
We found no significant difference between the human-rat or
human-mouse KA/KS distributions of the human 'immune'
and human 'immune disease' gene categories (P = 0.0897).
We then combined the disease and non-disease immune gene
sets and determined the KA/KS values of this larger immune-
system gene set compared to a set that included 7,641 non-
immune control genes that have 1:1:1 orthologous relation-
ships in mouse, rat and human. This control experiment con-
firmed our initial findings that the genes involved in the
human immune response contain, as a set, fewer members
subject to purifying selection than controls not involved in
immune function. Utilization of the larger gene set in this
analysis reduces the likelihood that results derive from sam-
pling error. We therefore conclude that elevation of KA/KS
values for disease genes of the immune system is a general
property of immunologically relevant genes, rather than
being specific to immune-system disease genes. This conclu-
sion is consistent with findings from studies demonstrating
that lymphocyte- or thymus-specific genes evolve relatively
rapidly [11,12].
Similar results were obtained for the human neurological-dis-
ease genes (data not shown): the significant KA/KS ratio dif-
ferences evident in Tables 3 and 4 are similar for human
genes involved in neurological processes and are not a
characteristic restricted to human neurological-disease
genes. Equivalent controls comparing genes associated with
neurological processes compared to a control group of all
non-neural orthologs similarly confirmed that the KA/KS ratio
differences are significant but are observed for all neurologi-
cally relevant genes.
From these studies, we conclude that KA/KS ratios differ sig-
nificantly for genes involved in either neurological or immune
processes as compared with the set of all genes examined (See
Materials and methods). Although less significant, differ-
ences in KA/KS ratio distributions were also identified for
three other gene sets: the malformation syndrome, pulmo-
nary and hematological categories. Genes in the neurological
and malformation-syndrome systems display, on average,
lower KA/KS ratios, whereas genes of the other three catego-
ries have, on average, higher KA/KS ratios. Thus, we conclude
that the pathophysiological system differences we observe
derive from organ, tissue and physiological characteristics
rather than arising from properties unique to disease genes
and their potential impact on fitness. Although these findings
are not specific to genes associated with human disease, they
could influence the selection of animal models used to inves-
tigate human disease.
Functional-annotation distribution by human disease 
system
Functional annotations can be examined in large-scale stud-
ies through the use of text mining and analysis tools. To this
end, we considered whether GO terms [30] and domain terms
were over- or under-represented for different disease sys-
tems. Results demonstrate that GO terms associated with
human disease genes demonstrate significant differences in
distribution across pathophysiological systems; for example,
annotations associated with cancer (DNA repair, cell prolifer-
ation, protein kinase and nucleus) were significantly over-
represented in this disease-gene category (see Figure 5).
Similarly, membrane protein, G protein-coupled receptors
(GPCR) and ion transport protein annotations were more fre-
quently associated with neurological disease genes. Figure 5
depicts over- or under-represented terms identified for each
pathophysiological system. Although many of these terms are
consistent with our current understanding of disease proc-
esses, text mining and analysis methods have the advantage
of defining comprehensive search profiles that can be applied
to genes of unknown function. From this analysis, we demon-
strate that domain, functional and gene-family annotations
are non-uniformly distributed across the pathophysiology
categories we have utilized and that these annotations closely
match what would be expected for current knowledge regard-
ing the unique disease processes that fall within the patho-
physiology underlying human disease.
Median KA/KS ratios for rat and mouse orthologs of human disease genes Figure 3
Median KA/KS ratios for rat and mouse orthologs of human disease genes. 
Median KA/KS values for each disease category are depicted for rat (color) 
and mouse (grey) demonstrating differences by disease category. The 
disease categories exhibiting the greatest purifying selection, the 
neurological and malformation-syndrome disease systems, show the 
lowest median KA/KS ratios.
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We considered subsequently whether the KA/KS differences
among pathophysiology system datasets described earlier
arose from over- or under-representation of specific domains,
functions or evolutionary families. For this we considered GO
terms [30] and domain terms. Results indicated that domain
names, or their annotations, did not account for differences
among median KA/KS values among pathophysiological sys-
tems. Thus, although gene-family, domain, and other func-
tional categories are non-uniformly distributed across the
pathophysiology groups, their distribution is not the underly-
ing cause of the KA/KS differences we observe.
Conservation of human disease genes in other model 
organisms
In addition to rodents, other animal models have also been
extensively used in the study of human diseases (see review
[31]). Given the utility and lower research costs for non-mam-
malian model organisms, we wished to determine the level of
conservation of disease genes in these established models. We
thus extended our analysis of rodent orthologs of human dis-
ease genes to a broader range of organisms including repre-
sentative genomes from fish, nematode, fly and yeast.
KA/KS differences by disease system Figure 4
KA/KS differences by disease system. Significance of KA/KS differences determined by Wilcoxon analysis indicate that both rat (color) and mouse (grey) 
demonstrate significantly strong purifying selection for the orthologs of the neurological and malformation-syndrome disease categories. The 
immunological, hematological, and pulmonary disease systems demonstrated significantly lower conservation. Disease categories are listed along the 
vertical axis in the order of standardized score from low to high. The P value is indicated above the bars in the figure; P values of less than 0.05 are 
considered statistically significant.
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Conservation metrics were selected for this analysis because
comparisons among more distantly-related organisms typi-
cally identify multiple substitutions per site, disallowing cal-
culation of KA/KS values from sequence pairs. We defined a
conservation index (CI, also known as a score density) as the
length-normalized amino-acid similarity between a sequence
pair (see Materials and methods). We predicted the number
of orthologs and quantiles of CI in each model organism spe-
cies (Additional data file 5). We then compared CI in different
disease systems for each of these organisms. Non-parametric
methods were used to calculate the standardized score for
each system in each organism similar to those applied in our
previous analyses.
With a 16-level Wilcoxon analysis, significant differences
between disease systems were identified for each of the spe-
cies tested. Of the 16 disease systems, five are the main con-
tributors to this difference: immune, hematological,
metabolic, neurological and malformation-syndrome. The CI
analysis (Table 3, Figure 6) recapitulates the findings from
human-rodent KA/KS results. The exception is that metabolic
genes appear to be evolving more slowly in invertebrates than
in vertebrates.
Thus, for the study of human diseases of immune and hema-
tological systems, primate or human cell models would
probably be most suitable. Rodent models are likely to be best
suited for studies of genes in neurological, malformation-syn-
drome and metabolic categories. Neurological and metabolic
genes are sufficiently well conserved that fly or fish models
are appropriate, whereas the yeast and worm, in general, are
perhaps best suited as models of metabolic diseases given the
overall lower conservation found for other categories in our
study.
These findings parallel previous studies [32,33] that con-
cluded that Drosophila  is a good model organism for the
study of genes in neurological and metabolic diseases, mal-
formation syndromes and cancer. However, these studies
based on 287 human disease genes categorized into 10 patho-
physiological systems used the percentage of orthologs
present per category to determine significance. By contrast,
our study, with a substantially larger disease-gene set and
more quantitative analysis, concluded that Drosophila  is
likely to have more limited utility as a model for the study of
human cancer processes.
Amino-acid-repeat expansions associated with human 
disease
Glutamine expansion is associated with a number of different
neurodegenerative disorders. In these diseases, long poly-
glutamine tracts result from the expansion of CAG triplets by
Table 3
Conservation index differences by disease system for model organisms
Disease system Mouse Rat Fish Fly Nematode Yeast
IDE -0.46 -0.49 -0.91 0.04 -0.52 -0.42
Bone_connectivetissue 1.14 0.04 -0.85 -1.70 -2.42 -0.26
Cancer -1.01 -1.42 -1.26 -0.85 -0.56 -0.01
Cardiovascular 0.90 -0.15 -1.33 -1.70 -0.72 -1.74
Endocrine -0.96 -0.30 0.19 -1.34 -1.81 -2.26
Hematological -5.05 -4.96 -0.68 -0.59 -0.21 0.59
Hepatic_GI_pancreatic -2.41 -2.67 -0.07 -1.01 -1.05 -1.36
Immune -6.93 -5.52 -5.81 -3.42 -1.52 0.05
Malformationsyndrome 4.17 3.06 0.09 -2.88 -3.67 -2.55
Metabolic 2.46 2.88 4.34 5.64 7.43 2.18
Muscle 3.24 2.24 0.87 -1.17 -0.66 1.42
Neurological 4.95 4.91 1.93 1.24 -0.30 0.55
Nonneuraleye 0.46 0.43 0.04 0.58 -1.00 -0.07
Other -0.87 -0.46 -1.46 -0.13 0.62 2.03
Pulmonary -3.67 -3.77 -0.34 -0.46 -3.03 -1.18
Renal -1.64 -1.26 -0.01 0.61 0.01 -0.52
Skin -1.52 -0.86 -0.25 -0.17 -0.09 0.04
Standardized scores from multi-level Wilcoxon analyses are shown. Categories that contribute to the global differences among systems with a 
sample size greater than 2% of the total are shown in bold, and were also used to generate Figure 6.R47.10 Genome Biology 2004,     Volume 5, Issue 7, Article R47       Huang et al. http://genomebiology.com/2004/5/7/R47
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trinucleotide slippage. To obtain a general picture of poly-
glutamine distribution and conservation in mammals, we
compared poly-glutamine tracts in human-rat, human-
mouse and rat-mouse ortholog p a i r s .  W e  u s e d  a l i g n e d
sequences to map equivalent (that is, orthologous) repeats
and considered tandem repeats either of length 5 or longer, or
of length 10 or longer ('very long repeats'). The two rodent
species contained a slightly lower number of glutamine
repeats than humans (85-88% of the number found in
humans), in accord with the generally lower frequency of tan-
dem amino-acid repeats in rodents as compared to humans
[34]. For very long glutamine repeats (more than 10 resi-
dues), we identified 40 repeats in human and 39 in mouse in
the human-mouse comparison; 41 in human and 58 in rat, in
the human-rat comparison; and, 83 in rat and 41 in mouse in
the rat-mouse comparison. Thus, among very long repeats, an
excess in human sequences was not detected and rat
sequences contained more repeats than mouse sequences.
The number of human glutamine repeats (repeat length 5 or
longer) conserved in rat and in mouse was roughly 55% in
both cases, slightly higher than the general human repeat
conservation level in rodents (46.5% for rat and 52% for
mouse).
We next compared glutamine-repeat length differences
among orthologous sequences containing very long human
glutamine repeats (Figure 7). Human glutamine-expansion-
disorder proteins all contain poly-glutamine tracts of 10 or
longer in the wild-type protein, except the androgen receptor,
which contains a repeat length of 5. In the case of disease-
associated genes, except for Machado-Joseph disease protein
(MJD), all repeats in the rat and mouse orthologs were less
than half the size of the human repeats (that is, those lying
below the line in Figure 7), an unexpected finding. Another
characteristic of disease-associated genes was that the region
encoding the repeat always contained a long CAG tract
(repeat length of 8 or longer). In addition, most of the dis-
ease-associated genes also contained repeats of other amino-
acid types. A group of other genes not known to be associated
with disease were found to share these same characteristics
(Table 4). Since these genes may also be subject to triplet-
repeat expansion in the human/primate lineage, they could
b e  i n v e s t i g a t e d  t o  determine if they are also involved in
human disease on the basis of their identification in this
study. Of special interest are the four that show EST support
for gene expression in the brain (identified by * in Table 4) as
these could potentially be associated with neurological
disease.
The comparison of poly-glutamine length in the three mam-
malian species studied has shown that human disease genes
that are associated with glutamine expansion are part of a
larger group of genes likely to have experienced repeat expan-
sions in the primate lineage. Examination of CAG and CAA
codon repeats in this dataset confirms that lineage-specific
glutamine repeats are associated with long CAG tracts
whereas those conserved among different lineages tend to be
encoded by a mixture of CAG/CAA codons [35]. Comparisons
Table 4
Human genes with poly-glutamine repeat tracts expanded in the human lineage and not at present known to be associated with disease
Gene name Gene symbol Ensembl reference LocusLink identifier
CAGH3 transcription factor TNRC3 ENSG00000179637 10292
DNA polymerase gamma subunit 1 NFYC ENSG00000140521* 4802
Decapping enzyme DCPIB ENSG00000151065* 196513
Nuclear receptor coactivator 3 NCOA3 ENSG00000124151 8202
Retina-derived POU-domain factor-1 RPF-1 ENSG00000106536* 11281
Retinoic acid induced 1 isoform 2 RAI2 ENSG00000108557* 10742
*EST (brain).
Functional annotation distribution by disease system Figure 5 (see following page)
Functional annotation distribution by disease system. Over-representation of gene ontology annotation in different disease systems. Only records with P 
value ≤0.05 and both expected and observed frequency ≥2%, and with number of records ≥5, are shown. Over-represented functions are labeled red with 
the color gradient representing the deviation in value. The darker the color, the greater the deviation observed.http://genomebiology.com/2004/5/7/R47 Genome Biology 2004,     Volume 5, Issue 7, Article R47       Huang et al. R47.11
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Figure 5 (see legend on previous page)
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of numbers of very long poly-glutamine repeats also indicate
that the rate of glutamine expansion in the rodent lineage
may be comparable to that in the human lineage, and that rat
sequences may be particularly prone to accumulate long
repeats, a desirable feature for transgenic models of triplet-
repeat expansion-associated disease. Such models already
exist for several such diseases [36-38]. This is in addition to
the advantage of using the rat, as opposed to the mouse, as an
animal model for the investigation of neurological disorders
for in vivo imaging studies because of its larger brain size
[38].
Conclusions
Almost all human disease genes have orthologous counter-
parts in rodent genomes. The set of these disease genes does
not differ greatly from the set of other genes with respect to
KA/KS ratios although significant differences in synonymous
substitution rates (KS) were observed. This suggests that
human disease gene sequences and their rat orthologs may
have mutated faster (or may have been repaired less effi-
ciently) than their non-disease counterparts. Although the
two KS distributions are significantly different, there is con-
siderable overlap between them; the median difference
between disease and non-disease distributions (0.05) is sig-
nificantly smaller than one standard deviation (0.20). This
means that the KS value of a particular gene, by itself, is not
likely to be a sufficient indicator of whether it is, or is not,
associated with disease.
Rodent orthologs of the gene set associated with neurological
function exhibit the greatest conservation and are primarily
subject to purifying selection. The highest KA/KS ratios were
observed for genes that function in the immune system indi-
cating that these genes are under less purifying selective pres-
sure. This finding would be expected if host-pathogen co-
evolution drives divergence by pathogen specificity within
species. If sequence divergence were to be coupled to func-
tional divergence, then this could suggest that rodent models
of human neurological disease are more likely to faithfully
represent human disease processes than rodent models of
immune disease. Rodent models of human diseases in the
immune-, hematological- and pulmonary-system pathophys-
iological categories should thus be validated particularly care-
fully before extrapolating from rodent studies to human.
Investigation of repeat-expansion disease genes led to the
observation that all rodent homologs of these human disease
genes bear shorter poly-glutamine repeat lengths.
Furthermore, glutamine repeats in the human disease genes
are mostly encoded by long CAG tracts. Rat-mouse-human
comparative analysis also identified a number of human
genes that, although not known to be associated with disease,
share the same repeat characteristics as human disease-asso-
ciated genes. These genes should be further investigated as
potential disease candidates; of special interest are the four
for which EST evidence indicates gene expression in the
brain. Spontaneous neurological diseases arising through
repeat-expansion mutations have not been identified in
either rat or mouse laboratory strains or in natural popula-
tions. This could be due to ascertainment bias of rare events
in rodent colonies or it is also possible that these orthologs fail
to achieve a 'critical repeat threshold' required to trigger these
mutational mechanisms. With the current successful devel-
opment of rodent transgenic models using human disease
gene constructs, this possibility can now be directly investi-
gated. It will also be instructive to define the normal variation
of rodent repeat lengths in natural populations for these
genes to determine whether the variation in repeat numbers
associated with a normal phenotype parallels that observed
for human.
Materials and methods
Validation of disease role and assignment of disease-
system annotation
The development of well-curated gene sets is an essential step
for genome-scale disease gene analysis. The starting point for
the present study was the Human Gene Mutation Database
(HGMD) (February 2003 release) [3]. Beginning with 1,178
disease genes in this database, each gene was checked for at
least one primary literature reference to confirm that it repre-
sented a bona fide gene in which a mutation had manifested
an experimentally confirmed disease-association. During the
annotation process, genes that did not meet this criterion
were placed in an IDE category (insufficient disease evidence)
but were not eliminated from the dataset. Thus, all genes that
were placed into pathological categories were independently
validated for disease association from the literature. Once a
gene had passed this validation step, it was placed into one or
more categories using the categorization method of Rubin et
al. [32] with minor modifications. Thus each gene was
assigned to one of the following categories: cancer, cardiovas-
cular, endocrine, hematological, immune, malformation-syn-
drome, metabolic, neurological, pulmonary, renal or other.
However, owing to the larger number of pathological systems
represented for the genes categorized in this study, the fol-
lowing categories were added to those used in the Drosophila
study [32]: skin, bone-connective tissue, muscle, hepatic-GI-
pancreatic, and nonneural eye. Annotation categories were
combined where they overlapped functionally (for example,
bone-connective tissue and hepatic-GI-pancreatic). Briefly,
the annotation method was to read the disease gene entry in
the Online Mendelian Inheritance in Man (OMIM) database
[4] to see if the pathophysiology category was identified in the
synopsis in sufficient depth to make an assignment. This
assignment was then confirmed using standard medical texts
covering internal medicine, pathology and infectious disease.
Annotations were independently determined by at least two
individuals and then all genes with discrepant annotations
were reviewed by the annotation group. In some cases, two
disease-system categories were assigned. For example, muta-http://genomebiology.com/2004/5/7/R47 Genome Biology 2004,     Volume 5, Issue 7, Article R47       Huang et al. R47.13
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tions in a number of enzyme-encoding genes produce human
disease within a narrow pathophysiological area. Thus, both
'metabolic' and the pathophysiology system directly associ-
ated with disease would be selected.
Human:rat ortholog pair assignment and KA/KS 
determination
cDNA 'reference sequences' corresponding to the protein-
coding entries in HGMD were mapped to NCBI build 31 of the
human genome sequence [39] using BLAT [14] and an align-
ment identity lower threshold of 95%. HGMD disease entries
were assigned Ensembl [13] human gene predictions if the
optimal mapping of their cDNA sequences overlapped at least
one Ensembl gene exon. Of the 11,522 1:1 rat:human
orthologs identified by Ensembl, 11,224 (97.4%) were identi-
fied as syntenic with human and are accepted with confi-
dence. The human disease genes in which orthologs were not
predicted by Ensembl were individually investigated further
using BLAT [14] and BLAST [15]. Additional 1:1 orthology
relationships were established or confirmed using rat
genome, EST, cDNA and protein sequences on the basis of
high amino-acid identity (most more than 80%). Given that
the median amino-acid identity among Ensembl's syntenic
human-rat orthologs is 88% [8], we are confident that the
ortholog assignments utilized in this study are accurate. KA/
KS and KS were calculated using the yn00 algorithm [40]
implemented in PAML [41] and pairwise alignments of
human and rat orthologs, described elsewhere [8].
Ortholog assignment and conservation index 
determination
Potential orthologs were searched for 1,180 disease genes in
the rat, mouse, fish, nematode, fly and yeast genomes using
the INPARANOID program [42]. A CI was calculated as the
alignment score in bits divided by the alignment length. The
number of potential orthologs and quantiles of CI were deter-
mined for each species. Although percentage sequence iden-
tity could also have been used for this purpose, CI has the
advantage of accounting for conservative substitutions. The
INPARANOID program utilized BLAST2 to generate align-
ments and employed the blosom62 amino acid substitution
matrix. Species utilized in this study and their on-line sources
are: Rattus norvegicus [43], Mus musculus [44], C. elegans
[45], Drosophila melanogaster [46], Saccharomyces cerevi-
siae [47] and Danio rerio [48].
Disease gene system conservation in model organisms Figure 6
Disease gene system conservation in model organisms. The five disease 
systems in which significant conservation differences are found 
(hematological, immune, malformation syndrome, metabolic and 
neurological) are plotted on the horizontal axis for the six different model 
organisms (mouse, rat, fish, fly, nematode and yeast). The vertical axis 
represents standardized score from Wilcoxon analyses for conservation 
index. The greater the score, the more conserved the disease system.
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Poly-glutamine repeat length comparison between human-rat and human- mouse orthologous proteins Figure 7
Poly-glutamine repeat length comparison between human-rat and human-
mouse orthologous proteins. Comparison of the poly-glutamine length 
between human-rat orthologous proteins (light orange, dark orange) and 
human-mouse orthologous proteins (light blue, dark blue). Dark orange 
and dark blue correspond to repeats in genes associated with repeat-
expansion disease in humans: SCA1, spinocerebellar ataxia 1 protein, or 
ataxin1; SCA2, spinocerebellar ataxia 2 protein; SCA7, spinocerebellar 
ataxia 7 protein; MJD, Machado-Joseph disease protein, or voltage-
dependent calcium channel gamma-1 subunit; CACNA1A, spinocerebellar 
ataxia 6 protein, or calcium channel alpha 1A subunit isoform 1; DRPLA, 
dentatorubro-pallidoluysian atrophy protein; HD, Huntington's disease 
protein, or huntingtin; TBP, TATA binding protein or spinocerebellar 
ataxia 17 protein. In the case of SCA2 the rat orthologous sequence did 
not contain the human amino-terminal region, wherein the repeat is 
located. Points below the diagonal line correspond to a repeat length that 
is more than double in humans versus rodents.
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Human disease mutation and rat wild-type genome-
sequence comparison
Human and rat ortholog alignments were inspected automat-
ically at positions described by HGMD as human disease
mutations. From this, 104 amino-acid sites were found to be
identical between the rat sequence and the proposed disease
variant in humans. These were investigated further by review
of the literature and the relevant HGMD entry. Questionable
items (marked as '?' in HGMD), and those for which there was
no documented statistical evidence for a causal connection
between sequence variation and a clinical phenotype, were
excluded, as were entries associated with poor alignment
quality.
Text analysis of functional annotation by disease-
system categories
Gene Ontology and domain terms were analyzed for over- or
under-representation in different disease systems using the
CoMet tool within the OmniViz analysis package [49]. This
analysis package analyzes associations between terms, cate-
gories, clusters and groups by examining the deviation of
number of occurrences in a cell from that found in a random
distribution; the resulting analyses are then visualized with
the CoMet tool which facilitates an overview of correlations
among a matrix of variables. Records meeting the criteria of:
P value less than or equal to 0.05, expected frequency greater
than or equal to 2%, observed frequency greater than or equal
to 2%, and record number greater than or equal to 5. For this
algorithm, the null hypothesis for a given GO entry would be:
'its frequency in a specific disease system is equal to its fre-
quency in others'. Results are portrayed graphically with
over-represented cells labeled in red. A gradient of color hue
represents the deviation in value for each category.
Identification of repeat-variation disease gene set
Genes with disease-associated mutations characterized as
bearing 'repeat variations' were retrieved from the HGMD
database [3]. The dataset included the nine different known
CAG-expansion disease genes. Protein and cDNA sequences
from humans, rat and mouse were obtained from the
Ensembl database [13]. In all, 11,501 human-rat sequence
pairs, 12,488 human-mouse sequence pairs and 12,357 rat-
mouse sequence pairs were aligned using CLUSTALW [50]
and glutamine tandem repeats mapped on the aligned
sequences. The length cut-off for considering repeats was five
or more glutamine residues in tandem. Conserved repeats
between two species were those with a length of 5 or longer in
an equivalent position in the two sequences.
Additional data files
The following additional data are available with the online
version of this article: the original set of 104 genes where rat
wild-type sequence is identical to human disease variant
mutation (Additional data file 1), the pathophysiology anno-
tations for human disease genes (Additional data file 2), the
list of immune-system genes not identified as disease genes
(Additional data file 3), the list of neurological-system genes
not identified as disease genes (Additional data file 4) and the
potential orthologs of human disease genes identified for
each model organism (Additional data file 5).
Additional data file 1 The original set of 104 genes where rat wild-type sequence is iden- tical to human disease variant mutationn The original set of 104 genes where rat wild-type sequence is iden- tical to human disease variant mutation Click here for additional data file Additional data file 2 The pathophysiology annotations for human disease genes The pathophysiology annotations for human disease genes Click here for additional data file Additional data file 3 The list of immune-system genes not identified as disease genes The list of immune-system genes not identified as disease genes Click here for additional data file Additional data file 4 The list of neurological-system genes not identified as disease  genes The list of neurological-system genes not identified as disease  genes Click here for additional data file Additional data file 5 The potential orthologs of human disease genes identified for each  model organism The potential orthologs of human disease genes identified for each  model organism Click here for additional data file
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